Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Stock Information for Coeptis Therapeutics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coeptis Therapeutics Holdings Inc.

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.